Introduction
============

Small cell lung cancer (SCLC) represents approximately 13-15% of all lung cancers [@B1], [@B2], and is characterized by rapid growth, early metastases, and poor prognosis [@B3]. The standard treatment in most of the patients with limited disease SCLC is the combination of chemotherapy and thoracic radiotherapy (RT) [@B4], [@B5]. However, local recurrences are reported to be as high as 50%, and the overall prognosis is poor [@B6]-[@B8]. Two randomized clinical trials (RCT) performed two decades ago have proven that there is no survival advantage of surgery compared with non-surgical treatment [@B9], [@B10]. However, recent data from some retrospective studies including several population database studies have demonstrated a potential benefit from surgery in patients with limited disease [@B11]-[@B19].

The positive role of prophylactic cranial irradiation (PCI) on long-term survival has been established for nonsurgical patients with limited disease and has been recommended by NCCN for patients who respond to treatment [@B20]. However, few studies have assessed the use of PCI for resected SCLC. Several retrospective studies have investigated the risk of brain metastasis according to the stage, but showed inconsistent results [@B21]-[@B25]. The value of PCI in this population needs further investigation.

Hence, this study aimed to assess the efficacy of surgery in stage II to III SCLC and evaluate the role of PCI in patients with resected SCLC.

Patients and methods
====================

Patients
--------

Between January 2010 and December 2015, 335 consecutive patients with limited stage SCLC were initially treated at our hospital. Most of the patients underwent standardized evaluation including thoracic and abdominal CT scanning or abdominal ultrasonography, brain magnetic resonance imaging (MRI) and bone radionuclide imaging, confirming the disease stage as stage II to III. TNM staging was determined according to the newly revised classification for lung cancer (American Joint Committee on Cancer seventh edition) [@B26]. Patients were excluded if they had stage IIIB disease (n=46), without pathological identification (n=5), who underwent incomplete resections (n = 4), who lost to follow-up or with missing or erroneous data (n = 11). After excluding, a total of 269 patients were included in this study. Of these, 153 underwent non-surgical treatment, and 116 received surgical resection. This retrospective study was approved by the Regional Ethics Committee of our institution, in compliance with the Helsinki Declaration (1996).

Treatment
---------

Of the 116 patients who underwent complete tumor resection followed by adjuvant chemotherapy or chemoradiotherapy, 98 (84.5%) received lobectomy, 11 (9.5%) received wedge resection and 7 (6.0%) received pneumonectomy. Among them, 61 (52.6%) received PCI. Of the 153 patients who underwent non-surgical treatment, all patients received chemotherapy combined with thoracic RT, and 99 (64.7%) received PCI. The most frequently administered chemotherapy regimen was cisplatin and etoposide (PE) either in surgical group or non-surgical group, for every 3 weeks cycle, and used for a total of 4-6 cycles. Three-dimensional conformal RT (3D-CRT)/intensity modulated RT (IMRT) was used for patients receiving thoracic RT. The prescribed dose for thoracic RT was 50-60 Gy in 2.0-Gy daily fractions for patients in non-surgical group and 46-56 Gy in 2.0-Gy daily fractions for patients in surgical group. The prescribed dose for PCI was 30-40Gy in 2.0-3.0Gy daily fractions.

Follow-up
---------

The last follow-up date was February 28, 2018. Most of the patients were followed up every 3-6 months for the first year, every 6 months for the next 2 years, and then annually until death. Survival information was collected via telephone if the patient could not visit the clinic on schedule.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS software version 24.0 (SPSS, Inc., Chicago, IL, USA). Overall survival (OS) was defined as the time from the initiation of treatment until death from any cause. Analysis of OS was carried out using the Kaplan-Meier method, and the difference between survival curves was tested by log-rank test. Variables with P \< 0.1 were included for multivariate analysis using the Cox regression model. To reduce the effects of selection bias and confounding factors, propensity score matching (PSM) was performed to compare the groups. Patients were matched according to the propensity scores based on age, sex, TNM stage, and ECOG score with 1:1 ratio using the nearest neighbor matching method [@B27]. For all analyses, P \< 0.05 was considered statistically significant.

Results
=======

Characteristics of the study population before and after matching are shown in Table [1](#T1){ref-type="table"}. Characteristics of the study population before and after matching between surgical and NST groups are shown in Table [2](#T2){ref-type="table"}. ECOG score, N stage, and TNM stage in the overall study cohort were significantly different between surgical and NST groups (Table [2](#T2){ref-type="table"}). The PSM cohort (including 70 patients in surgical group and 70 patients in non-surgical group) showed an expected balance of covariates in the two groups (Table [2](#T2){ref-type="table"}). The detailed treatment regimens for the two groups before and after matching are shown in Table [3](#T3){ref-type="table"}. For surgical group, matched patients receiving adjust chemo-radiation was relatively more than non-matched patients (71.4% vs. 50%). For NST group, the treatment was similar between matched and non-matched patients.

The response rates \[complete response (CR) + partial response (PR)\] were 74.5% (114/153) in non-surgical group. Median follow-up for all patients was 30 months (range, 3-87 months), with 32 months (range, 3-79 months) for surgical group patients, and 28 months (range, 5-87 months) for the non-surgical group patients.

Survival
--------

The median survival for all patients was 30 months, with 38 months for the surgical group, and 28 months for the non-surgical group patients. The 1-, 3- and 5-year OS rates were 82.8%, 50.7% and 38.8% for surgical group, and 83.0%, 37.7% and 24.9% for non-surgical group (P=0.029), respectively, which showed statistical significance. These findings were confirmed in the matched patients. The median survival for all patients was 23 months, with 32 months for the surgical group, and 20 months for the non-surgical group. The 1-, 3- and 5-year OS were 80.0%, 44.3.0% and 31.7% for surgical group, and 80.0%, 24.3% and 20.0% for non-surgical group (P=0.009; Fig. [1](#F1){ref-type="fig"}A), respectively, which showed statistical significance.

Analysis of factors related to OS
---------------------------------

Univariate analysis of all and matched patients demonstrated that surgery (P=0.029 and P=0.009) and PCI (P=0.03 and P=0.037) were significantly associated with improved OS (Tables [4](#T4){ref-type="table"}, 5). Lower TNM stage was significantly considered to be a positive prognostic factor for all patients (P=0.024; Table [4](#T4){ref-type="table"}).

In multivariate Cox regression analysis, PCI was an independent prognostic factor for OS of all \[hazards ratio (HR)=0.665, 95% confidence interval (CI): 0.492-0.899; (Table [4](#T4){ref-type="table"}) and matched patients (HR=0.637, 95%CI: 0.427-0.950; Table [5](#T5){ref-type="table"}). Additionally, surgery was an independent prognostic factor in matched patients (HR=0.603, 95%CI: 0.404-0.900; Table [5](#T5){ref-type="table"}).

Subgroup analysis of matched patients (Table [6](#T6){ref-type="table"}) demonstrated a marginal OS benefit from surgery for stage II (P=0.09; Fig. [1](#F1){ref-type="fig"}B) and IIIA (P=0.061; Fig. [1](#F1){ref-type="fig"}C). A significantly improved OS was observed for selected stage IIIA patients who received adjuvant chemoradiotherapy and PCI in surgical group when compared with stage IIIA patients in non-surgical group (P=0.01; Fig. [1](#F1){ref-type="fig"}D).

Improved OS related to PCI was found for non-surgical patients (P=0.036), but not for surgical patients (P=0.172; Table [7](#T7){ref-type="table"}; Fig. [2](#F2){ref-type="fig"}A). Further subgroup analysis of surgical patients demonstrated a survival advantage with the use of PCI in stage IIIA patients (P=0.047; Table [7](#T7){ref-type="table"}; Fig. [2](#F2){ref-type="fig"}B).

Discussion
==========

The role of surgery for limited-stage SCLC remains controversial due to lack of conclusive evidence. A recent review by Barnes et al. examined three RCTs [@B9], [@B10], [@B28] that evaluated surgery versus nonoperative management for SCLC [@B29]. The study concluded that the current evidence does not support a role for surgical resection in the management of limited-stage SCLC. However, these RCTs were conducted more than two decades ago were of very low quality and had some limitations. For example, for the Fox\' trial [@B9], chemotherapy was not included as part of the standard treatment protocol, and only 34/71 participants underwent surgical resection in the surgical arm. Since the time these trials were conducted, there have been many developments in SCLC therapy such as modern RT technique, and better diagnostic and surgical tools. Recently, data from a series of observational studies have supported a role for surgery in the management of limited-stage SCLC [@B11]-[@B19]. In the present study, the 1-, 3- and 5-year OS rates in surgical group were significantly higher than in non-surgical group. The survival benefits from surgery were maintained in the propensity matched patients.

As SCLC responds well to chemotherapy and radiotherapy, surgery is considered to be a standard treatment option mainly for early stage SCLC. Current NCCN guidelines have recommended surgical resection for clinical stage I (T1-2, N0) disease [@B20]. However, no consensus was drawn for the role of surgery in stage II and stage III diseases. Gaspar, et al. [@B30] analyzed the National Cancer Database (NCDB) and found that surgery was significantly associated with improved survival in patients with stage II and stage III SCLC. Conversely, another NCDB based Propensity-Matched Analysis for limited-stage SCLC [@B11] showed that surgery was related to longer survival time for stage I patients, but survival differences were attenuated for stage II and IIIA. However, in their study, only 35.5% received lobectomy, and less than 50% of stage IIIA surgical patients were adjusted for chemo-radiation. A retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) between 1988 and 2002 identified 863 patients with SCLC who underwent surgery [@B13]. Results revealed that lobectomy was associated with the best outcomes, and there was a significant survival benefit from the addition of PORT in patients with N2 disease. In our study, most of the matched surgical patients with stage IIIA were adjusted for chemo-radiation, and all surgical patients underwent complete tumor resection, and 85.7% of them received lobectomy. All these findings might help to improve OS for surgical patients. We found a marginal OS benefit from surgery for stages II and IIIA patients. In further subgroup analysis of stage IIIA, a significantly improved OS from surgery was observed in patients who received adjuvant chemo-radiation and PCI (P=0.01). These results suggested a potential OS benefit of surgery in stages II and IIIA, particularly in selected stage IIIA patients.

The positive role of PCI has been recognized for patients with limited SCLC who respond to treatment. However, few studies have investigated the value of PCI for resected disease. Several scholars have retrospectively assessed the risk of brain relapse after surgery for limited SCLC, suggesting that PCI might have a role in surgically resected stages (p-stage) II and III patients because of their relatively high frequency of brain metastasis, but not for stage (p-stage) I disease due to lower incidence of brain metastases [@B22]-[@B25],[@B31]-[@B32]. In the present study, PCI was considered to be an independent prognostic factor for OS. Improved OS related to PCI was found for non-surgical patients, but not for surgical patients. However, further subgroup analysis showed a survival advantage with the use of PCI in patients with stage IIIA (P=0.047).

Our study has several limitations. Firstly, this is a retrospective analysis. However, we performed PSM, which eliminated potential bias by creating two comparable groups. Secondly, modern tools such as positron emission tomography-computed tomography (PET-CT) or mediastinoscopy were not routinely used. Therefore, the diagnosis of clinical stage was less accurate.

Conclusions
===========

In summary, these results suggest a potential OS benefit of surgery in stages II and IIIA patients, particularly in selected stage IIIA patients who received adjuvant chemoradiotherapy and PCI. The use of PCI for surgical patients with stage IIIA was associated with improved OS. Further prospective RCTs are needed to confirm these findings.

![Comparison of OS between NST group and surgical group in matched patients. A: all; B: stage II; C: stage IIIA; D: selected stage IIIA. NST: non-surgical treatment; selected stage IIIA: surgical patients who received adjuvant chemo-radiation and prophylactic cranial irradiation.](jcav09p3500g001){#F1}
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###### 

Characteristics of the study population before and after matching

  Characteristic    Before Matching(n=269)      After Matching(n=140)
  ----------------- ------------------------ -- -----------------------
  Sex                                           
  Male              173(64.3)                   81(57.9)
  Female            96(35.7)                    59(42.1)
  Age                                           
  ≥60               92(34.2)                    47(33.6)
  \<60              177(65.8)                   93(66.4)
  Smoking history                               
  Yes               176(65.4)                   88(62.9)
  No                93(34.6)                    52(37.1)
  ECOG score                                    
  0-2               259(96.3)                   140(100)
  3                 10(3.7)                     0(0)
  Tumor location                                
  Central           122(45.4)                   61(43.6)
  Peripheral        147(54.6)                   79(56.4)
  T stage                                       
  T1                51(19.0)                    24(17.1)
  T2                116(43.1)                   67(47.9)
  T3                97(36.1)                    49(35.0)
  T4                5(1.8)                      0(0)
  N stage                                       
  N0                43(16.0)                    19(13.6)
  N1                86(32.0)                    39(27.9)
  N2                140(52.0)                   82(58.6)
  TNM Stage                                     
  II                84(31.2)                    38(27.1)
  IIIA              185(68.8)                   102(72.9)
  Treatment                                     
  Surgical          116(43.1)                   70(50)
  NST               153(56.9)                   70(50)

Abbreviations: NST: non-surgical treatment.

###### 

Characteristics of the study population before and after matching between surgical and NST groups.

  Characteristic    Before Matching(n=269)               After Matching (n=140)                              
  ----------------- ------------------------ ----------- ------------------------ -- ----------- ----------- -------
  Sex                                                                                                        
  Male              77(66.4)                 96(62.7)    0.538                       38(54.3)    43(61.4)    0.392
  Female            39(33.6)                 57(37.3)                                32(45.7)    27(38.6)    
  Age                                                                                                        
  ≥60               36(31.0)                 56(36.6)    0.340                       25(35.7)    22(31.4)    0.591
  \<60              80(69.0)                 97(63.4)                                45(64.3)    48(68.6)    
  Smoking history                                                                                            
  Yes               75(64.7)                 101(66.0)   0.817                       43(61.4)    45(64.3)    0.726
  No                41(35.3)                 52(34.0)                                27(38.6)    25(35.7)    
  ECOG score                                                                                                 
  0-2               116(100.0)               143(93.5)   0.013                       70(100.0)   70(100.0)   \--
  3                 0(0.0)                   10(6.5)                                 0(0.0)      0(0.0)      
  Tumor location                                                                                             
  Central           48(41.4)                 74(48.4)    0.254                       32(45.7)    29(41.4)    0.609
  Peripheral        68(58.6)                 79(51.6)                                38(54.3)    41(58.6)    
  T stage                                                                                                    
  T1                22(19.0)                 29(19.0)    0.227                       9(12.9)     15(21.4)    0.148
  T2                54(46.6)                 62(40.5)                                39(55.7)    28(40.0)    
  T3                40(34.4)                 57(37.3)                                22(31.4)    27(38.6)    
  T4                0(0)                     5(3.2)                                  0(0)        0(0)        
  N stage                                                                                                    
  N0                28(24.1)                 15(9.8)     \<0.001                     9(12.9)     10(14.3)    0.352
  N1                43(37.1)                 43(28.1)                                16(22.9)    23(32.9)    
  N2                45(38.8)                 95(62.1)                                45(64.3)    37(52.9)    
  TNM stage                                                                                                  
  II                65(56.0)                 19(12.4)    \<0.001                     19(27.1)    19(27.1)    1.00
  IIIA              51(44.0)                 134(87.6)                               51(72.9)    51(72.9)    

Abbreviations: NST: non-surgical treatment.

###### 

The initial treatment before and after matching

  Treatement               Before Matching, N(%)   After Matching, N(%)
  ------------------------ ----------------------- ----------------------
  Surgical group (n=116)                           
  Surgical schedule                                
  Surgery only             11(9.5)                 5(7.1)
  Surgery + CT             47(40.5)                15(21.4)
  Surgery + CRT            58(50.0)                50(71.4)
  Surgical procedure                               
  lobectomy                98 (84.5)               60(85.7)
  wedge resection          11 (9.5)                6(8.6)
  pneumonectomy            7 (6.0)                 4(5.7)
  PCI                                              
  Yes                      61(52.6)                44(62.9)
  No                       55(47.4)                26(37.1)
  NST group (n=153)                                
  NST schedule                                     
  CT only                  0(0)                    0(0)
  RT only                  0(0)                    0(0)
  CRT                      153(100)                70(100)
  PCI                                              
  Yes                      99(64.7)                44(62.9)
  No                       54(35.3)                26(37.1)

Abbreviations: NST: non-surgical treatment; CT: chemotherapy; RT: radiotherapy; CRT: chemoradiotherapy; PCI: prophylactic cranial irradiation.

###### 

Univariate and multivariate analysis of factors related to OS (before matching, n=269)

  Variable          No.   1-Yr (%)   3-Yr (%)   5-Yr (%)   Univariate   Multivariate         
  ----------------- ----- ---------- ---------- ---------- ------------ -------------------- -------
  Sex                                                                                        
  Male              173   79.8       40.1       28.3       0.169                             
  Female            96    88.5       49.1       34.7                                         
  Age                                                                                        
  ≥60               92    79.3       39.9       25.1       0.180                             
  \<60              177   84.7       45.1       33.6                                         
  Smoking history                                                                            
  Yes               176   80.1       41.3       31.5       0.652                             
  No                93    88.2       47.0       29.5                                         
  Tumor location                                                                             
  Central           122   83.6       42.4       30.6       0.962                             
  Peripheral        147   82.3       44.2       30.9                                         
  T Stage                                                                                    
  T1                51    90.2       41.8       35.5       0.161                             
  T2                116   83.6       48.8       34.8                                         
  T3                97    80.4       37.9       23.7                                         
  T4                5     40.0       40.0       40.0                                         
  N Stage                                                                                    
  N0                43    79.1       46.2       34.4       0.470                             
  N1                86    88.4       43.8       35.6                                         
  N2                140   80.7       41.9       26.4                                         
  TNM Stage                                                                                  
  II                84    85.7       51.2       41.0       0.024        0.713(0.478-1.062)   0.096
  IIIA              185   81.6       39.7       25.7                                         
  Surgery                                                                                    
  Yes               116   82.8       50.7       38.8       0.029        0.808(0.563-1.158)   0.246
  No                153   83.0       37.7       24.9                                         
  PCI                                                                                        
  Yes               160   83.8       48.8       35.5       0.030        0.665(0.492-0.899)   0.008
  No                109   81.7       35.2       23.0                                         

Abbreviations: PCI: prophylactic cranial irradiation.

###### 

Univariate and multivariate analysis of factors related to OS (after matching, n=140)

  Variable          No.   1-Yr (%)   3-Yr (%)   5-Yr (%)   Univariate      Multivariate         
  ----------------- ----- ---------- ---------- ---------- ------------ -- -------------------- -------
  Sex                                                                                           
  Male              81    76.5       30.7       21.7       0.325                                
  Female            59    84.7       39.8       31.6                                            
  Age                                                                                           
  ≥60               47    74.5       30.9       17.2       0.414                                
  \<60              93    82.8       36.0       30.8                                            
  Smoking history                                                                               
  Yes               88    78.4       34.1       27.0       0.894                                
  No                52    82.7       34.6       24.7                                            
  Tumor location                                                                                
  Central           61    78.7       37.5       28.7       0.612                                
  Peripheral        79    81.0       31.8       23.7                                            
  T Stage                                                                                       
  T1                24    87.5       26.5       26.5       0.176                                
  T2                67    80.6       42.9       31.6                                            
  T3                49    75.5       26.0       17.1                                            
  N Stage                                                                                       
  N0                19    84.2       35.1       26.3       0.789                                
  N1                39    84.6       32.6       23.2                                            
  N2                82    76.8       35.0       27.6                                            
  TNM Stage                                                                                     
  II                38    84.2       39.9       31.1       0.081           0.648(0.409-1.026)   0.064
  IIIA              102   78.4       32.1       24.4                                            
  Surgery                                                                                       
  Yes               70    80.0       44.3       31.7       0.009           0.603(0.404-0.900)   0.013
  No                70    80.0       24.3       20.0                                            
  PCI                                                                                           
  Yes               88    84.1       40.2       32.6       0.037           0.637(0.427-0.950)   0.027
  No                52    73.1       25.0       14.4                                            

Abbreviations: PCI: prophylactic cranial irradiation.

###### 

Comparison of survival between surgical and NST group by stage (after matching)

                         N     1-Yr (%)   3-Yr (%)   5-Yr (%)   P value
  ---------------------- ----- ---------- ---------- ---------- ---------
  Stage II               38                                     
  Surgical               19    94.7       47.8       35.9       0.09
  NST                    19    73.7       31.6       25.3       
  Stage IIIA             102                                    
  Surgical               51    74.5       42.6       30.2       0.061\*
  Surgical-selected^a^   35    77.1       50.7       40.3       0.010\*
  NST                    51    82.4       21.6       19.6       

Abbreviations: NST: non-surgical treatment; a: stage IIIA patients who received adjuvant chemoradiotherapy and prophylactic cranial irradiation in surgical group; \*: compared with NST.

###### 

Comparison of survival by PCI

                        N     1-Yr (%)   3-Yr (%)   5-Yr (%)   P value
  --------------------- ----- ---------- ---------- ---------- ---------
  NST                   153                                    
  PCI(+)                99    83.8       43.4       30.7       0.036
  PCI(-)                54    81.5       27.0       13.2       
  Surgical              116                                    
  PCI(+)                61    83.6       57.9       43.4       0.172
  PCI(-)                55    81.8       43.0       33.8       
  Surgical-stage IIIA   51                                     
  PCI(+)                35    80.0       50.8       35.9       0.047
  PCI(-)                16    62.5       25.0       18.8       

Abbreviations: NST: non-surgical treatment; PCI: prophylactic cranial irradiation.
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